Results 261 to 270 of about 2,451,260 (295)
Some of the next articles are maybe not open access.
New Antivirals and Drug Resistance
Annual Review of Biochemistry, 2009Progress in the discovery of new antiviral medicines is tempered by the rapidity with which drug-resistant variants emerge. A review of the resistance-suppressing properties of four classes of antivirals is presented: influenza virus neuraminidase inhibitors, HIV protease inhibitors, antibodies, and protein-based fusion inhibitors.
openaire +2 more sources
Antiviral resistance and direct-acting antiviral agents for HCV
Antiviral Therapy, 2012Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development. DAA treatment of HCV infection, however, leads to the selection of viral variants (produced by the error-prone HCV polymerase) that are resistant to the DAA agent in use ...
Aloia, A., Locarnini, S., Beard, M.
openaire +3 more sources
Computational Coevolution of Antiviral Drug Resistance
Artificial Life, 1998An understanding of antiviral drug resistance is important in the design of effective drugs. Comprehensive features of the interaction between drug designs and resistance mutations are difficult to study experimentally because of the very large numbers of drugs and mutants involved.
Christopher D. Rosin +4 more
openaire +2 more sources
Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals
Clinical and Diagnostic Virology, 1993Testing cytomegaloviruses for antiviral susceptibility is increasing especially since the reports of 'resistance' to ganciclovir and foscarnet (Erice et al., 1989; Knox et al., 1991). There is however no standardized method for susceptibility testing nor are there criteria for designating an isolate as sensitive or resistant.
W L, Drew, R, Miner, E, Saleh
openaire +2 more sources
Pediatric Infectious Disease Journal, 2008
Antivirals are effective in prophylaxis and therapy for influenza and are likely to be active against a new pandemic variant. They can be divided into the M2 inhibitors, adamantane and rimantadine, and the neuraminidase inhibitors (NAIs), zanamivir and oseltamivir. The former are limited in activity to type A viruses, whereas the latter are also active
openaire +2 more sources
Antivirals are effective in prophylaxis and therapy for influenza and are likely to be active against a new pandemic variant. They can be divided into the M2 inhibitors, adamantane and rimantadine, and the neuraminidase inhibitors (NAIs), zanamivir and oseltamivir. The former are limited in activity to type A viruses, whereas the latter are also active
openaire +2 more sources
Models of antiviral resistance
Antiviral Research, 1995D W, Kimberlin +4 more
openaire +2 more sources
Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward
Ca-A Cancer Journal for Clinicians, 2021Amila K Nanayakkara, David E Greenberg
exaly
Understanding the Impact of Resistance to Influenza Antivirals.
Clinical Microbiology Reviews, 2021Edward C. Holmes +2 more
exaly
Antiviral resistance — an emerging problem
Antiviral Research, 1995D W, Kimberlin, R J, Whitley
openaire +2 more sources